proprotein
convertas
pc
respons
endoproteolyt
process
variou
protein
precursor
eg
growth
factor
receptor
adhes
molecul
matrix
metalloproteinas
implic
sever
diseas
obes
diabet
atherosclerosi
cancer
alzheim
diseas
potenti
clinic
pharmacolog
role
pc
foster
develop
variou
pcinhibitor
review
summar
recent
find
pc
inhibitor
mode
action
potenti
use
therapi
variou
diseas
proprotein
convertas
pc
serin
proteas
bellow
kexin
subfamili
subtilas
enzym
respons
process
activ
multipl
polypeptid
precursor
secretori
precursor
usual
cleav
gener
motif
kr
x
n
kr
x
amino
acid
except
c
n
repres
cleavag
site
peptid
hydrolyz
date
seven
basic
amino
acid
aa
specif
pc
serin
proteas
belong
kexin
subfamili
subtilas
report
involv
process
includ
furin
also
call
also
call
also
call
lpc
recent
two
nonbasicaaspecif
convertas
identifi
convertas
belong
pyrolysin
proteinas
k
subfamili
subtilas
respect
found
exhibit
cleavag
specif
motif
rk
x
hydrophob
l
base
autocatalyt
site
seem
prefer
vfaq
motif
review
role
proprotein
convertas
mediat
diseas
briefli
summar
mode
action
natur
exogen
inhibitor
describ
potenti
use
new
target
treatment
variou
diseas
discuss
recent
pc
link
neurodegen
disord
via
direct
indirect
role
product
amyloidogen
peptid
alzheim
diseas
amyloidb
ab
princip
compon
senil
plaqu
latter
gener
proteolyt
cleavag
precursor
band
gsecretas
recent
pc
found
process
zymogen
aand
bsecretas
suggest
implic
pc
diseas
involv
proprotein
convertas
tumorigenesi
extens
review
cleav
protein
precursor
pc
matrix
metalloproteas
adhes
molecul
growth
factor
growth
factor
receptor
directli
indirectli
involv
tumorigenesi
metastasi
regul
either
degrad
extracellular
matrix
andor
modul
cell
growth
surviv
use
differ
tumor
cell
invasivemetastat
phenotyp
inhibit
pcactiv
found
provok
dramat
chang
sever
phenotyp
impact
metastat
potenti
tumor
cell
similarli
use
variou
sitedirect
mutagenesi
found
inhibit
process
sever
pc
substrat
pdgfa
vegfc
reduc
significantli
abil
induc
tumor
develop
angiogenesi
respect
data
highlight
import
pc
activ
growth
factor
tumor
progress
angiogenesi
c
bacteri
toxin
activ
pc
three
differ
class
bacteri
toxin
describ
activ
pc
toxin
first
class
synthes
singl
polypeptid
chain
group
toxic
subunit
target
bind
subunit
toxin
precursor
cleav
interact
target
cell
surfac
endosom
compart
pc
toxin
belong
class
report
activ
pc
diptheria
toxin
pseudomona
aeruginosa
exotoxin
pea
botulinum
neurotoxin
bordetella
dermonecrot
toxin
second
class
toxin
anthrax
synthes
separ
polypeptid
chain
usual
assembl
target
cell
surfac
form
activ
toxin
follow
activ
bind
subunit
pc
third
class
group
poreform
toxin
aerolysin
toxin
produc
secret
dimer
bind
target
cell
glycosylphosphatidyl
inositol
anchor
membran
protein
usual
cleavag
toxin
pc
occur
surfac
target
cell
bind
process
seem
crucial
associ
toxin
dimer
heptam
pore
complex
caus
cell
lysi
previous
data
variou
infecti
virus
reveal
cleavag
envelop
glycoprotein
precursor
one
pc
requir
step
acquisit
infecti
capac
viral
particl
inde
variou
studi
demonstr
capac
pc
correctli
cleav
varieti
viral
surfac
glycoprotein
includ
surfac
glycoprotein
hong
kong
ebola
viru
sever
acut
respiratori
syndrom
coronaviru
parallel
studi
reveal
inhibit
process
viral
surfac
glycoprotein
pc
inhibitor
decrvkrcmk
complet
abrog
virusinduc
cellular
cytopath
recent
surfac
glycoprotein
virus
particularli
hemorrhag
fever
virus
arenavirida
famili
lassa
crimean
congo
hemorrhag
fever
lymphocyt
choriomening
shown
cleav
convertas
similarli
blockad
activ
specif
inhibitor
also
shown
affect
process
stabil
glycoprotein
virus
sinc
discoveri
furin
grow
evid
pc
implic
variou
patholog
process
made
enzym
import
potenti
therapeut
target
therebi
variou
attempt
made
develop
specif
potent
inhibitor
target
enzym
inhibitor
found
develop
far
group
natur
endogen
exogen
pc
inhibitor
date
natur
occur
intracellular
pc
inhibitor
found
constitut
secretori
pathway
pc
propeptid
proseg
previous
report
mani
protein
use
propeptid
intramolecular
chaperon
correct
fold
transport
andor
secret
addit
proseg
function
enzym
fragment
also
report
act
inhibitor
variou
enzym
includ
pc
like
substrat
pc
synthes
inact
proenzym
autocatalyt
activ
follow
signal
sequenc
remov
endoplasm
reticulum
er
fold
event
pc
undergo
autoproteolyt
cleavag
proseg
fig
proseg
howev
remain
associ
matur
domain
enzym
function
potent
autoinhibitor
transport
late
secretori
pathway
step
inact
complex
transit
late
transgolgi
network
tgn
rel
acid
ph
permit
second
autoproteolyt
cleavag
proseg
activ
convertas
fig
use
inhibitor
abl
inhibit
process
function
variou
pc
substrat
pdgfa
pdgfb
vegfc
receptor
fig
recent
furin
inhibit
proseg
profurin
report
feasibl
approach
reduc
andor
abolish
malign
phenotyp
variou
malign
inde
express
complet
profurin
cdna
sequenc
variou
human
head
neck
squamou
cell
carcinoma
cell
line
found
reduc
dramat
prolifer
tumorigen
invas
vitro
vivo
well
profurin
effect
directli
link
inhibit
furinmedi
activ
variou
crucial
cancerrel
substrat
tgfb
vegfc
receptor
littl
known
cellular
function
nevertheless
brak
marten
first
show
act
chaperon
abl
bound
latter
earli
compart
secretori
pathway
dissoci
latter
one
studi
propos
may
also
facilit
transport
endoplasm
reticulum
secretori
granul
particip
gener
fulli
activ
follow
secret
interact
er
presenc
alkalin
ph
form
inact
complex
progress
tgn
presenc
decreas
ph
increas
ca
cleav
pc
releas
ctermin
fragment
inhibitori
function
secretori
granul
addit
ph
decreas
ca
increas
permit
self
activ
liber
prodomain
provid
fulli
activ
fig
subsequ
ntermin
domain
ctermin
domain
rapidli
degrad
carboxypeptidas
e
fig
prosaa
natur
occur
inhibitor
like
prosaa
contain
ntermin
ctermin
domain
separ
pc
cleavag
site
sequenc
respons
inhibitori
potenc
previous
point
hexapeptid
llrvkr
locat
prosaa
ctermin
domain
peptid
identifi
combinatori
librari
peptid
screen
tight
bind
site
like
inact
endoplasm
reticulum
golgi
apparatu
due
neutral
ph
rel
low
ca
level
addit
interact
prosaa
follow
progress
tgn
prosaa
cleav
two
peptid
design
pen
len
fragment
remov
inhibit
prosaa
fig
interalphainhibitor
protein
ialphaip
abund
endogen
serin
proteas
inhibitor
initi
isol
human
plasma
ialphaip
consist
three
polypeptid
two
heavi
chain
one
light
chain
call
bikunin
analysi
bikunin
structur
reveal
presenc
two
proteas
domain
kunitz
type
carri
antiproteolyt
function
ialphaip
bikunin
found
effect
broad
rang
enzym
includ
trypsin
chymotrypsin
plasmin
leukocyt
elastas
well
cathepsin
b
h
although
crystal
structur
analysi
bikunin
reveal
direct
interact
trypsin
two
domain
bikunin
inhibitori
mechan
ialphaip
remain
unknown
recent
ialphaip
also
propos
good
inhibitor
furin
prevent
format
activ
anthrax
lethal
toxin
inde
inhibitor
abl
provid
signific
protect
cytotox
murin
periton
macrophag
expos
high
dose
anthrax
lethal
toxin
fig
initi
studi
indic
serpin
proteinas
inhibitor
abl
inhibit
varieti
proteinas
differ
mechan
inhibitor
shown
inactiv
porcin
trypsin
human
thrombin
human
coagul
factor
xa
bacillu
subtili
dibas
endoproteinas
subtilisin
serpin
report
form
sdsstabl
complex
human
furin
provok
inhibit
enzym
furin
inhibit
due
presenc
reactiv
site
domain
inhibitor
pc
cleavag
site
name
exogen
inhibitor
proprotein
convertas
gener
act
competit
fashion
inhibitor
contain
gener
cleavag
motif
pc
kr
x
n
kr
presenc
alkalin
ph
poor
environ
free
interact
form
inact
complex
progress
transgolgi
network
tgn
ph
decreas
ca
increas
cleav
pc
ctermin
fragment
remain
attach
secretori
granul
sg
ph
lower
ca
higher
cleav
autocatalyt
liber
prodomain
fragment
ntermin
domain
ctermin
ntermin
domain
rapidli
degrad
carboxypeptidas
e
gener
fulli
activ
synthet
inhibitor
contain
structur
acyl
moieti
allow
enter
cell
bind
activ
site
pc
peptidyl
group
first
compound
demonstr
inhibit
pc
member
famili
deriv
decanoylrvlrchloromethylketon
found
inhibit
variou
pc
substrat
rang
growth
factor
viral
glycoprotein
inhibitor
previous
use
inhibit
activ
variou
mmp
tumor
cell
invas
process
similarli
treatment
prostat
cancer
cell
line
reagent
found
inhibit
process
prostatederiv
factor
pdf
member
tgfb
superfamili
associ
loss
prostat
cancer
cell
differenti
recent
polyarginin
also
describ
potent
inhibitor
pc
base
report
structur
mous
furin
activ
site
enzym
seem
contain
extend
substratebind
groov
line
mani
neg
charg
residu
therebi
highli
acid
charact
substratebind
groov
explain
highinhibitori
potenc
posit
charg
polyargininecontain
peptid
recent
hexadarginin
amid
found
inhibit
significantli
pseudomona
aeruginosa
exotoxin
pea
process
peainduc
toxic
mice
also
polyarginin
inhibitor
report
abl
inhibit
process
human
immunodefici
replic
viru
well
turkey
ovomucoid
third
domain
normal
reactiv
site
known
potent
inhibitor
variou
serin
proteinas
includ
subtilisin
chymotrypsin
elastas
mutat
inhibitor
reactiv
site
made
strong
inhibitor
trypsin
mutat
site
made
strong
inhibitor
gluspecif
streptomyc
griseu
proteinas
glusgp
fig
parallel
introduct
proprotein
convertas
site
structur
made
moder
furin
inhibitor
fig
eglin
c
proteinas
inhibitor
strongli
inhibit
human
leukocyt
elastas
cathepsin
g
achymotrypsin
substilisin
inhibitor
initi
isol
leech
hirudo
medicinali
belong
potato
inhibitor
famili
previous
report
inhibitori
specif
could
chang
inhibit
trypsin
point
mutat
reactiv
site
subsequ
substitut
residu
posit
eglin
c
basic
residu
made
strong
inhibitor
furin
recent
gener
threedimension
complex
structur
furineglin
c
mutant
interact
model
program
provid
crucial
inform
interact
furin
inhibitor
model
interact
allow
calcul
electrostat
interact
energi
furin
eglin
c
mutant
result
obtain
studi
highlight
import
chargecharg
interact
bind
furin
inhibitor
suggest
role
electrostat
interact
inhibitori
activ
eglin
c
mutant
toward
furin
analysi
reveal
mutat
residu
eglin
c
seem
increas
inhibitori
action
eglin
c
mutant
due
electrostat
interact
furin
fig
discoveri
inhibitor
initi
base
observ
previous
report
patient
mutat
patient
shown
unabl
cleav
proalbumin
furin
consensu
site
variant
call
pittsburgh
pit
replac
reactivesit
residu
residu
subsequ
group
g
thoma
develop
anoth
variant
call
portland
reactivesit
aipm
replac
ripr
serpin
reveal
inhibit
furin
ki
pm
three
time
lower
pit
inhibitor
subsequ
kinet
analysi
show
portion
bound
oper
suicid
inhibitor
fig
bound
furin
activ
site
either
undergo
proteolysi
furin
form
kinet
trap
sdsstabl
complex
enzym
furthermor
express
cell
shown
potent
inhibitor
furinmedi
cleavag
hiv
gp
subsequ
demonstr
inhibit
pc
involv
process
within
constitut
secretori
pathway
vitro
experi
reveal
also
abil
block
process
variou
protein
relat
tumor
progress
metastasi
sever
growth
factor
fig
receptor
variou
mmp
adhes
molecul
synthet
peptid
design
develop
reactiv
site
loop
pc
inhibitor
way
contain
pc
cleavag
motif
make
circular
peptid
cy
residu
insert
termin
residu
sever
minipdx
peptid
vitro
digest
analysi
presenc
variou
synthet
pc
substrat
reveal
minipdx
abl
inhibit
vitro
furin
activ
slow
tightbind
manner
contrari
pc
inhibitor
synthet
peptid
seem
inhibit
furin
via
differ
mechanist
pathway
requir
investig
human
homotetramer
glycoprotein
present
high
concentr
blood
monomer
subunit
contain
intern
sester
ise
inhibit
wide
rang
proteas
uniqu
mechan
inhibit
initi
cleavag
flexibl
surfaceaccess
peptid
stretch
call
bait
region
fig
cleavag
trigger
hydrolysi
ise
follow
major
conform
chang
proteas
becom
trap
inhibitor
thu
steric
shield
substrat
introduc
furin
recognit
sequenc
bait
region
van
rompaey
et
al
gener
potent
pc
inhibitor
reveal
abil
inhibit
process
von
willebrand
factor
glycoprotein
late
reveal
mutat
introduc
bait
region
interfer
neither
fold
neither
tetramer
inhibitor
also
furin
inhibit
mechan
mutant
found
similar
use
inhibit
proteas
fig
diterpin
first
report
nonprotein
inhibitor
furin
neoandrographolid
extract
medicin
activ
plant
andrographi
paniculata
succinoyl
ester
deriv
fig
actual
mechan
diterpin
exert
inhibitori
effect
pc
clearli
understood
nevertheless
molecul
contain
reactiv
fivememb
lacton
ring
found
sever
elastas
inhibitor
suggest
potenti
role
lacton
ring
furin
activ
inhibit
although
vitro
inhibit
rel
weak
compound
seem
penetr
easili
cell
might
enhanc
inhibitori
potenti
vivo
compound
recent
shown
interest
degre
convertas
select
new
class
nonpeptid
inhibitor
consist
ion
cu
zn
coupl
chelat
compound
fig
inhibit
furin
compound
irrevers
inhibitor
bind
enzym
activ
site
enzym
inde
analysi
furin
sequenc
reveal
presenc
activ
site
residu
abl
bind
dival
zinc
copper
includ
catalyt
last
year
cumul
knowledg
reveal
implic
proprotein
convertas
variou
disord
includ
diabet
atherosclerosi
cancer
famili
hypercholesterolemia
viral
infect
alzheim
diseas
therebi
use
gener
pc
inhibitor
suggest
advantag
could
promis
therapeut
strategi
howev
case
may
necessari
target
one
member
pc
famili
feasibl
demonstr
previous
prosaa
addit
recent
publish
crystal
structur
furin
undoubtedli
help
search
design
develop
specif
potent
inhibitor
pc
inde
avail
crystal
structur
furin
recent
reveal
preciou
knowledg
characterist
pc
model
structur
base
studi
arrang
catalyt
p
domain
architectur
substrat
bind
cleft
furin
seem
similar
less
similar
follow
develop
specif
inhibitor
could
use
alon
combin
target
pcmediat
diseas
recent
studi
reveal
small
molecul
proprotein
convertas
inhibitor
attract
potenti
therapeut
agent
howev
diterpen
sever
cu
zn
chelat
report
nonpeptid
pc
inhibitor
although
inhibitor
abl
inhibit
activ
pc
vitro
abil
block
process
variou
pc
substrat
vivo
yet
test
similarli
improv
specif
efficaci
inhibitor
chemic
modif
structur
follow
structureact
studi
requir
long
term
potenti
develop
specif
potent
pc
inhibitor
may
provid
rational
test
famili
compound
therapeut
agent
conjunct
standard
therapi
clinic
set
work
support
fondat
pour
la
recherch
avenir
award
pari
franc
